Tech Company Financing Transactions
Prime Medicine Funding Round
Arch Venture Partners, Casdin Capital and Cormorant Asset Management participated in a $200 million Series B capital raise for Prime Medicine. The round closed on 7/14/2021.
Transaction Overview
Company Name
Announced On
7/14/2021
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Series B
Investors
Proceeds Purpose
The funds raised will be used to continue building the company, rapidly advance towards clinical indications, expand the capabilities of the platform, and to further enhance the exceptional promise of Prime Editing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
21 Erie St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can search and replace to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Keith Gottesdiener
Chief Scientific Officer
Jeremy Duffield
Co-Founder
Andrew Anzalone
VP - General Counsel
Karen Brown
VP - Operations
Meredith Goldwasser
Browse more venture capital transactions:
Prev: 7/14/2021: AttackIQ venture capital transaction
Next: 7/15/2021: Morty venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs